Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Arpin

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2004
A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysisLine Claude, David Pérol, Chantal Ginestet, et al.
Bulletin Du Cancer|August 6, 2009
[A difficult end of life]Julie Traclet, Dominique Arpin, Laurence Gérinière, et al.
Bulletin Du Cancer|August 6, 2009
[Confidentiality in medical practice: tell no one]Sébastien Couraud, Dominique Arpin, Maurice Perol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitisDominique Arpin, David Perol, Jean-Yves Blay, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
Therapeutic Advances in Medical Oncology|July 21, 2020
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" studyDominique Arpin, Marie-Christine Charpentier, Marie Bernardi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2004
A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysisLine Claude, David Pérol, Chantal Ginestet, et al.
Bulletin Du Cancer|August 6, 2009
[A difficult end of life]Julie Traclet, Dominique Arpin, Laurence Gérinière, et al.
Bulletin Du Cancer|August 6, 2009
[Confidentiality in medical practice: tell no one]Sébastien Couraud, Dominique Arpin, Maurice Perol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitisDominique Arpin, David Perol, Jean-Yves Blay, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
Therapeutic Advances in Medical Oncology|July 21, 2020
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" studyDominique Arpin, Marie-Christine Charpentier, Marie Bernardi, et al.
Pageof 2